Skip to main content
Top
Published in: PharmacoEconomics 3/2011

01-03-2011 | Original Research Article

Comparing Methods of Data Synthesis

Re-Estimating Parameters of an Existing Probabilistic Cost-Effectiveness Model

Authors: Mark Oppe, Maiwenn Al, Maureen van Rutten-Mölken

Published in: PharmacoEconomics | Issue 3/2011

Login to get access

Abstract

Background: Cost-effectiveness models should always be amendable to updating once new data on important model parameters become available. However, several methods of synthesizing data exist and the choice of method may affect the cost-effectiveness estimates.
Objectives: To investigate the impact of the different methods of metaanalysis on final estimates of cost effectiveness from a probabilistic Markov model for chronic obstructive pulmonary disease (COPD).
Methods: We compared four different methods to synthesize data for the parameters of a cost-effectiveness model for COPD: frequentist and Bayesian fixed-effects (FE) and random-effects (RE) meta-analyses. These methods were applied to obtain new transition probabilities between stable disease states and new event probabilities.
Results: The four methods resulted in different estimates of probabilities and their standard errors (SE). The effects of using different synthesis techniques were most prominent in the estimation of the SEs. We found up to 9-fold differences in SEs of the exacerbation probabilities and up to almost 3-fold differences in SEs of the transition probabilities. We found that the frequentist FE model produced the lowest SEs, whereas the Bayesian RE model produced the highest for all parameters. The estimates of differences between treatments in total costs, QALYs and cost-effectiveness acceptability curves (CEAC) also varied depending on the synthesis method. The CEAC was 15% lower with a Bayesian RE model than with any of the other models.
Conclusions: Health economic modellers should be aware that the choice of synthesis technique can affect resulting model parameters considerably, which can in turn affect estimates of cost effectiveness and the uncertainty around them.
Appendix
Available only for authorised users
Literature
2.
go back to reference Rutten-van Mölken M, Lee TA. Economic modeling in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006 Sep; 3 (7): 630–4CrossRef Rutten-van Mölken M, Lee TA. Economic modeling in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006 Sep; 3 (7): 630–4CrossRef
3.
go back to reference Oostenbrink JB, Rutten-van Molken MP, Monz BU, et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005; 8: 32–46PubMedCrossRef Oostenbrink JB, Rutten-van Molken MP, Monz BU, et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005; 8: 32–46PubMedCrossRef
4.
go back to reference Rutten-van Mölken MP, Oostenbrink JB, Miravitlles M, et al. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ 2007; 8: 123–35CrossRef Rutten-van Mölken MP, Oostenbrink JB, Miravitlles M, et al. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ 2007; 8: 123–35CrossRef
5.
go back to reference Oostenbrink JB, Al MJ, Oppe M, et al. Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research. Value Health 2008; 11: 1070–80PubMedCrossRef Oostenbrink JB, Al MJ, Oppe M, et al. Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research. Value Health 2008; 11: 1070–80PubMedCrossRef
6.
go back to reference Riley RD, Simmonds MC, Look MP. Evidence synthesis combining individual patient data and aggregate data: a systematic review identified current practice and possible methods. J Clin Epidemiol 2007; 60: 431–9PubMed Riley RD, Simmonds MC, Look MP. Evidence synthesis combining individual patient data and aggregate data: a systematic review identified current practice and possible methods. J Clin Epidemiol 2007; 60: 431–9PubMed
7.
go back to reference Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–88CrossRef Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–88CrossRef
8.
go back to reference Sutton AJ, Abrams K, Jones DR, et al. Methods for meta-analysis in medical research. London: Wiley, 2000 Sutton AJ, Abrams K, Jones DR, et al. Methods for meta-analysis in medical research. London: Wiley, 2000
9.
go back to reference Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 year’s treatment with tiotropium. Eur Respir J 2002; 19: 209–16PubMedCrossRef Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 year’s treatment with tiotropium. Eur Respir J 2002; 19: 209–16PubMedCrossRef
10.
go back to reference Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217–24PubMedCrossRef Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217–24PubMedCrossRef
11.
go back to reference Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399–404PubMedCrossRef Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399–404PubMedCrossRef
12.
go back to reference Scanlon PD, Connett JE, Waller LA, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000; 161: 381–90 Scanlon PD, Connett JE, Waller LA, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000; 161: 381–90
13.
go back to reference Bateman E, Singh D, Smith D, et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis 2010; 5: 197–208PubMed Bateman E, Singh D, Smith D, et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis 2010; 5: 197–208PubMed
14.
go back to reference Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002 Jun 15; 21 (11): 1539–58PubMedCrossRef Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002 Jun 15; 21 (11): 1539–58PubMedCrossRef
15.
go back to reference Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–60PubMedCrossRef Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–60PubMedCrossRef
16.
go back to reference Gelman A, Carlin JB, Stern HS, et al. Bayesian data analysis. London: Chapman & Hall, 1995 Gelman A, Carlin JB, Stern HS, et al. Bayesian data analysis. London: Chapman & Hall, 1995
17.
go back to reference Carlin BP, Louis TA. Bayes and emperical Bayes methods for data analysis. London: Chapman & Hall, 1996 Carlin BP, Louis TA. Bayes and emperical Bayes methods for data analysis. London: Chapman & Hall, 1996
18.
go back to reference Kreft IGG, Leeuw JD. Introducing multilevel modeling. Thousand Oaks (CA): Sage, 1998 Kreft IGG, Leeuw JD. Introducing multilevel modeling. Thousand Oaks (CA): Sage, 1998
19.
go back to reference Spiegenhalter DJ, Best NG, Carlin BP, et al. Bayesian measures of model complexity and fit. J R Stat Soc B 2002; 64: 1–34CrossRef Spiegenhalter DJ, Best NG, Carlin BP, et al. Bayesian measures of model complexity and fit. J R Stat Soc B 2002; 64: 1–34CrossRef
20.
go back to reference Fenwick E, Briggs A. Cost-effectiveness acceptability curves in the dock: case not proven? Med Decis Making 2007; 27: 93–5PubMedCrossRef Fenwick E, Briggs A. Cost-effectiveness acceptability curves in the dock: case not proven? Med Decis Making 2007; 27: 93–5PubMedCrossRef
21.
go back to reference Arends LR. Multivariate meta-analysis: modelling the heterogeneity. Mixing apples and oranges: dangerous or delicious? [PhD thesis]. Alblasserdam: Haveka BV, 2006 Arends LR. Multivariate meta-analysis: modelling the heterogeneity. Mixing apples and oranges: dangerous or delicious? [PhD thesis]. Alblasserdam: Haveka BV, 2006
22.
go back to reference Ades AE, Sculpher M, Sutton A, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006; 24 (1): 1–19PubMedCrossRef Ades AE, Sculpher M, Sutton A, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006; 24 (1): 1–19PubMedCrossRef
23.
go back to reference Gelman A. Prior distributions for variance parameters in hierarchical models. Bayesian Anal 2006; 1: 515–33CrossRef Gelman A. Prior distributions for variance parameters in hierarchical models. Bayesian Anal 2006; 1: 515–33CrossRef
24.
go back to reference Browne WJ, Draper D. A comparison of Bayesian and likelihood-based methods for fitting multilevel models. Bayesian Anal 2006; 1: 473–514CrossRef Browne WJ, Draper D. A comparison of Bayesian and likelihood-based methods for fitting multilevel models. Bayesian Anal 2006; 1: 473–514CrossRef
Metadata
Title
Comparing Methods of Data Synthesis
Re-Estimating Parameters of an Existing Probabilistic Cost-Effectiveness Model
Authors
Mark Oppe
Maiwenn Al
Maureen van Rutten-Mölken
Publication date
01-03-2011
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 3/2011
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/11539870-000000000-00000

Other articles of this Issue 3/2011

PharmacoEconomics 3/2011 Go to the issue

Adis Pharmacoeconomic Drug Evaluation

Posaconazole